Palantir's UN Contract Extension Collides With a Wall Street Valuation Standoff
Published on 08/08/2026 at 18:31 | Redaktion boerse-global.de
The United Nations World Food Programme is preparing to extend and expand its data analytics agreement with Palantir Technologies, according to reports on Saturday — a decision that lands with awkward timing, coming just as a leaked internal audit has raised unspecified concerns about the company's practices. The move signals that even when red flags surface within public institutions, Palantir's deepening entrenchment in government and multilateral circles appears resilient.
That institutional foothold is precisely what powered the software maker's latest earnings report, which has ignited one of the sharpest valuation debates on Wall Street this season. On Monday, Palantir posted second-quarter revenue of $1.935 billion, a 93 percent surge year over year and well ahead of the $1.80 billion consensus estimate. US government sales climbed 90 percent to $809 million, while American commercial revenue jumped 149 percent to $764 million. Net income swung from $326.7 million to $1.06 billion. Chief executive Alex Karp framed the results in characteristically bold terms, describing the business as having "nearly doubled in twelve months" and predicting the momentum would persist for "at least another 18 months."
The numbers have split the analyst community more dramatically than most technology stocks typically manage. Bank of America holds a Buy rating with a $255 price target, while Morgan Stanley sits at Equal-Weight with a $205 target. At the bearish extreme, RBC carries an Underperform rating and a $90 target, and Jefferies' Brent Thill — despite lifting his target from $70 to $80 — remains cautious. Thill points to a steepening growth hurdle: Palantir will be measured against a 67 percent growth baseline in the second half of 2026, but that comparison climbs to 89 percent by the first half of 2027, a pace he considers unsustainable. The skepticism extends beyond sell-side desks. Star investor Michael Burry said publicly on Wednesday that he wished he had shorted $1 billion worth of Palantir shares, while ARK Invest trimmed its position.
Institutional behavior tells a more nuanced story. Several funds reduced their stakes during the second quarter, and insiders sold roughly $150.7 million worth of stock over a 90-day window. Yet Vanguard and State Street added to their holdings, suggesting the bearish camp remains a minority voice.
Should investors sell immediately? Or is it worth buying Palantir?
The valuation question sits at the center of the debate. Citi's Tyler Radke raised his price target from $200 to $245 but flagged that Palantir trades at roughly 70 times expected revenue — a level he calls stretched. UBS, which lifted its target to $220, justifies the multiple differently, pointing to about 44 times revised 2027 free cash flow. The company's operating metrics are undeniably strong: a record Rule of 40 score of 155 percent, adjusted free cash flow of $1.22 billion in the quarter, and 220 deals worth over $1 million closed, including 98 above $5 million and 70 above $10 million. The pipeline of open US commercial contract negotiations has more than doubled to $6.24 billion. Management guided third-quarter revenue to $2.16–$2.164 billion with adjusted operating income of $1.292–$1.296 billion, and full-year adjusted free cash flow of $4.5–$4.7 billion. The full-year revenue forecast was also raised sharply, from $7.65–$7.662 billion to $8.15–$8.158 billion.
Growth catalysts extend beyond the balance sheet. Palantir and Mercury Systems are collaborating on a US military-funded Tradewind prototype agreement to automate factory operations using the Foundry platform. Separately, Reuters reports that Palantir and Anduril are forming a consortium with SpaceX, OpenAI, and other technology firms to challenge established Pentagon suppliers.
The risks, however, are not purely a matter of multiples. Britain's National Health Service is reportedly preparing to revise how it measures the success of Palantir's data platform, following employee discoveries of errors in underlying statistics — several hospital trusts have already acknowledged data inaccuracies. The $444 million contract could face political pressure if an exit clause is triggered in early 2027, though no decision has been made. Elsewhere, public clients including New York's hospital system, the Dutch defense ministry, and authorities in France and Denmark have either declined to renew contracts or are actively seeking alternatives. Palantir also lost 22 of 23 disputed points in a legal battle with the investigative platform Republik. A free open-source analytics tool called "World Monitor" briefly spooked the market over questions about government pricing, knocking the stock down around 6 percent at one point.
Palantir at a turning point? This analysis reveals what investors need to know now.
The German listing captured the post-earnings enthusiasm, closing Friday at €148.84, up 9.88 percent on the day and roughly 39 percent over the past seven sessions. Even after that run, the shares remain 17.30 percent below their 52-week high of €179.98 reached in early November. With an RSI of 72.2, the stock is technically overbought.
The WFP decision now becomes something of a test case: whether concerns about data practices can slow Palantir's government momentum, or whether customers and investors will continue to weigh the growth trajectory more heavily than the criticism. The third-quarter guidance range of $2.16–$2.164 billion offers the next concrete checkpoint — hitting it could push the valuation debate to the background, while missing it would likely bring the 70-times-revenue question roaring back.
Ad
Palantir Stock: New Analysis - 8 August
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
